B. Riley started coverage on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a research note published on Wednesday. The brokerage issued a buy rating and a $2.75 price objective on the biotechnology company’s stock.
A number of other analysts also recently weighed in on ATNM. Maxim Group set a $3.00 price target on shares of Actinium Pharmaceuticals and gave the company a buy rating in a report on Wednesday. HC Wainwright reissued a buy rating and issued a $6.00 price target on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd. Finally, Roth Capital reissued a buy rating and issued a $6.00 price target on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd.
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) traded down $0.02 during midday trading on Wednesday, hitting $0.67. 951,700 shares of the company traded hands, compared to its average volume of 713,054. Actinium Pharmaceuticals has a fifty-two week low of $0.54 and a fifty-two week high of $1.72.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
What are top analysts saying about Actinium Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Actinium Pharmaceuticals Inc and related companies.